Search
Pelecopan
go.drugbank.com/drugs/DB21573ExperimentalThe usage of the INN stem '-copan' in the name indicates that Pelecopan is a complement receptor antagonist/complement inhibitor. Pelecopan has a monoisotopic molecular weight of 406.13 Da.
Envonalkib
go.drugbank.com/drugs/DB21585ExperimentalThe usage of the INN stem '-alkib' in the name indicates that Envonalkib is a ALK (anaplastic lymphoma kinase) inhibitor. Envonalkib has a monoisotopic molecular weight of 505.14 Da.
Zurletrectinib
go.drugbank.com/drugs/DB21601ExperimentalThe usage of the INN stem '-trectinib' in the name indicates that Zurletrectinib is a tropomyosin receptor kinase (TRK) inhibitor. Zurletrectinib has a monoisotopic molecular weight of 415.16 Da.
Rolusafine
go.drugbank.com/drugs/DB21617ExperimentalThe usage of the INN stem '-afine' in the name indicates that Rolusafine is a antifungal squalene mono-oxygenase inhibitor. Rolusafine has a monoisotopic molecular weight of 306.14 Da.
Merigolix
go.drugbank.com/drugs/DB21628ExperimentalThe usage of the INN stem '-golix' in the name indicates that Merigolix is a gonadotropin releasing hormone (GnRH) antagonist. Merigolix has a monoisotopic molecular weight of 752.24 Da.
Lerzeparib
go.drugbank.com/drugs/DB21650ExperimentalThe usage of the INN stem '-parib' in the name indicates that Lerzeparib is a poly-ADP-Ribose polymerase inhibitor. Lerzeparib has a monoisotopic molecular weight of 365.15 Da.
Nurandociguat
go.drugbank.com/drugs/DB21720InvestigationalThe usage of the INN stem '-ciguat' in the name indicates that Nurandociguat is a guanylate cyclase activator and stimulator. Nurandociguat has a monoisotopic molecular weight of 571.25 Da.
Lobeline
go.drugbank.com/drugs/DB05137InvestigationalAn alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent.
Apricitabine
go.drugbank.com/drugs/DB12855InvestigationalApricitabine has been used in trials studying the treatment of HIV Infections.
AGT-182
go.drugbank.com/drugs/DB17630InvestigationalAGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.